CDK10 is not a target for aberrant DNA methylation in breast cancer

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 3939-3944

  Heller, Gerwin ^a   Ziegler, Barbara ^a   Brandstetter, Anita ^a   Novak, Sabine ^a   Rudas, Margaretha ^b   Hennig, Guido ^c   Gehrmann, Mathias ^c   Acht, Torsten ^c   Zöchbauer Müller, Sabine ^a   Filipits, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c SIEMENS AG   (Germany)

Author keywords

Breast cancer; CDK10; Cyclin dependent kinase; DNA methylation; Tamoxifen

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 10; DAL 1 PROTEIN; ESTROGEN RECEPTOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASES; DNA METHYLATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; RNA, MESSENGER;

EID: 71949098919     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Clarke R, Leonessa F, Welch JN and Skaar TC: Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53: 25-71, 2001. (Pubitemid 32173107)
2. Butt AJ, McNeil CM, Musgrove EA and Sutherland RL: Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12(Suppl 1): S47-59, 2005.
3. Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R and Filipits M: High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol 21: 3594-3600, 2003. (Pubitemid 46594051)
4. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R and Michalides RJ: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405-415, 1997. (Pubitemid 27131382)
5. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ and Bernards R: Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12: 3488-3498, 1998.
6. Wilcken NR, Prall OW, Musgrove EA and Sutherland RL: Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 3: 849-854, 1997.
7. Bindels EM, Lallemand F, Balkenende A, Verwoerd D and Michalides R: Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Oncogene 21: 8158-8165, 2002. (Pubitemid 35454418)
8. Hui R, Finney GL, Carroll JS, Lee CS, Musgrove EA and Sutherland RL: Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 62: 6916-6923, 2002. (Pubitemid 35424081)
9. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL and Robertson JF: Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 5: 2069-2076, 1999. (Pubitemid 29399260)
10. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO and Landberg G: Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90: 1942-1948, 2004.
11. Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O and Landberg G: Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 65: 8009-8016, 2005. (Pubitemid 41297281)
12. Ahnstrom M, Nordenskjold B, Rutqvist LE, Skoog L and Stal O: Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Treat 91: 145-151, 2005. (Pubitemid 40684926)
13. Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF and Filipits M: Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 14: 1767-1774, 2008.
14. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ and Ashworth A: Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13: 91-104, 2008. (Pubitemid 351163160)
15. Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196, 1998.
16. Heller G, Fong KM, Girard L, Seidl S, End-Pfutzenreuter A, Lang G, Gazdar AF, Minna JD, Zielinski CC and Zöchbauer-Müller S: Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 25: 959-968, 2006. (Pubitemid 43237714)
17. Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, Fritz P, Stoerkel S and Schaefer KL: RNA Extraction from Archival Formalin-Fixed Paraffin-Embedded Tissue: A Comparison of Manual, Semiautomated, and Fully Automated Purification Methods. Clin Chem, 2009. Doi:10.1373/clinchem.2008.122572
18. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
19. Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431, 2002.
20. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF and Minna JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255, 2001. (Pubitemid 32095725)
21. Heller G, Fong KM, Girard L, Seidl S, End-Pfutzenreuter A, Lang G, Gazdar AF, Minna JD, Zielinski CC and Zöchbauer-Müller S: Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 25: 959-968, 2006. (Pubitemid 43237714)
22. Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699, 2001. (Pubitemid 32492810)
23. Lin NU and Winer EP: Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26: 798-805, 2008. (Pubitemid 351264393)
24. van Engeland M, Weijenberg MP, Roemen GM, Brink M, de Bruine AP, Goldbohm RA, van den Brandt PA, Baylin SB, de Goeij AF and Herman JG: Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res 63: 3133-3137, 2003. (Pubitemid 36735864)